Reuters reveals Shionogi moves to develop its own U.S. sales staff - Reuters News Agency

Reuters reveals Shionogi moves to develop its own U.S. sales staff

Reuters reported exclusively how Shionogi, Japan’s most profitable drugmaker by operating margin, is being prodded into seizing more sales for itself instead of relying on bigger partners, as a key HIV drug and three combination medicines will open to generic competition in nine years time. The company plans to develop its own U.S. sales team for cefiderocol, an antibiotic it hopes will gain approval this year and which will be used as a last-resort treatment for patients with infectious disease not cured by other antibiotics, CEO Isao Teshirogi told Reuters in an interview.

Article Tags
Type: Reuters Best
Sectors: Equities
Regions: Asia
5d30c7ad-f4d4-4d6c-8201-0b47ac130004
Sign up for email updates
Subscribe
Sign up for email updates